Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Evolutionary Proteogenomic Landscape from Pre-invasive to Invasive Lung Adenocarcinoma

ABSTRACT: We conducted a comprehensive proteogenomic analysis comprising proteomic and phosphoproteomic profiling on 98 pre-invasive and 99 invasive lung adenocarcinomas.

ORGANISM(S): Homo Sapiens

SUBMITTER: Chen Ding

PROVIDER: PXD047518 | iProX | Tue Dec 05 00:00:00 GMT 2023

REPOSITORIES: iProX

ACCESS DATA

Json Xml

Similar Datasets

Intercepting progression from pre-invasive to invasive lung adenocarcinoma

Project description:Intercepting progression from pre-invasive to invasive lung adenocarcinoma

| PRJNA808146 | ENA

Intercepting progression from pre-invasive to invasive lung adenocarcinoma

Project description:Intercepting progression from pre-invasive to invasive lung adenocarcinoma

| PRJNA808147 | ENA

Proteogenomic landscape of medulloblastoma subgroups

Project description:Proteogenomic landscape of medulloblastoma subgroups

| PRJNA420382 | ENA

Proteogenomic landscape of medulloblastoma subgroups [methylation]

Project description:Proteogenomic landscape of medulloblastoma subgroups [methylation]

| PRJNA413673 | ENA

Proteogenomic landscape of medulloblastoma subgroups [SNP]

Project description:Proteogenomic landscape of medulloblastoma subgroups [SNP]

| PRJNA420381 | ENA

Genomic and immune profiling of pre-invasive lung adenocarcinoma

Project description:Adenocarcinoma in situ and minimally invasive adenocarcinoma are the pre-invasive forms of lung adenocarcinoma. The genomic and immune profiles of these lesions are poorly understood. Here we report exome and transcriptome sequencing of 98 lung adenocarcinoma precursor lesions and 99 invasive adenocarcinomas. We have identified EGFR, RBM10, BRAF, ERBB2, TP53, KRAS, MAP2K1 and MET as significantly mutated genes in the pre/minimally invasive group. Classes of genome alterations that increase in frequency during the progression to malignancy are revealed. These include mutations in TP53, arm-level copy number alterations, and HLA loss of heterozygosity. Immune infiltration is correlated with copy number alterations of chromosome arm 6p, suggesting a link between arm-level events and the tumor immune environment.

| EGAS00001004006 | EGA

Proteogenomic Landscape of Squamous Cell Lung Cancer

Project description:Proteogenomic Landscape of Squamous Cell Lung Cancer

| PRJNA520937 | ENA

Proteogenomic Landscape of Squamous Cell Lung Cancer

Project description:Proteogenomic Landscape of Squamous Cell Lung Cancer

| PRJNA520938 | ENA

Proteogenomic Characterization Reveals Estrogen Signaling as a Target for Never-Smoker Lung Adenocarcinoma Patients without EGFR or ALK Alterations [MethylationEPIC]

Project description:Never-smoker lung adenocarcinoma (NSLA) is prevalent in Asian populations, and is even more in women. EGFR mutations and ALK fusions are major alterations observed in NSLA. We have focused on NSLA without EGFR and ALK alteration (NENA) rather than NSLA with EGFR and ALK (EA). First, we selected 141 NSLA tissues, and performed proteogenomic analyses including the whole-genome sequencing (WGS), transcriptome, methylation EPIC array, total proteome and phosphoproteome. We then excluded 40 patients with EA and 7 patients with NENA microsatellite instability. Genome analysis revealed that TP53 (25%), KRAS (22%), ROS1 fusion (14%), and SETD2 (11%) were the most frequently mutated genes in NENA patients. Proteogenomic impact analysis revealed that STK11 and ERBB2 somatic mutations had broader effects on cancer-associated genes in NENA. Through DNA copy-number alteration analysis, we identified 22 prognostic proteins, inﬂuencing transcriptomic and proteomic changes. Gene set enrichment analysis revealed that the estrogen signaling emerged as the key pathway activated in NENA. A lot of proteogenomic evidence supported the increased estrogen signaling, such as copy-number deletions in chromosomes 14 and 21, STK11 mutation, and DNA hypomethylation of LLGL2 and ST14. Finally, saracatinib, an Src inhibitor, was suggested as a potential drug for targeting activated estrogen signaling in NENA, and was experimentally validated in vitro using cell line model. In this study, we enhanced our understanding of the etiology of NENA NSLA through the proteogenomic landscape, based on which we proposed saracatinib as an effective drug

2024-03-11 | GSE256092 | GEO